Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 27, 2019 - Issue 5
Submit an article Journal homepage
235
Views
13
CrossRef citations to date
0
Altmetric
Original Articles

Two Novel CAPN5 Variants Associated with Mild and Severe Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Phenotypes

Nadia M. Randazzo MBBCh, BSc(Hons)NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom;Oxford Eye Hospital, University of Oxford NHS Trust, John Radcliffe Hospital, Oxford, United KingdomCorrespondence[email protected]
View further author information
,
Morag E. Shanks PhDOxford Medical Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust Churchill Hospital, Oxford, United KingdomView further author information
,
Penny Clouston PhD, FRCPathOxford Medical Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust Churchill Hospital, Oxford, United KingdomView further author information
&
Robert E. MacLaren MB ChB, DPhil, FRCOphthNIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom;Oxford Eye Hospital, University of Oxford NHS Trust, John Radcliffe Hospital, Oxford, United KingdomView further author information
Pages 693-698 | Received 07 Apr 2017, Accepted 19 Aug 2017, Published online: 17 Oct 2017

References

  • Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open. 2014;4(2):e004015.
  • Simonelli F, Maguire AM, Testa F; et al. Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther. 2010;18(3):643–650.
  • Conlon TJ, Deng W-T, Erger K; et al. Preclinical potency and safety studies of an AAV2-Mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. Hum Gene Ther Clin Dev. 2013;24(1):23–28.
  • MacLaren RE, Groppe M, Barnard AR; et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet. 2014;383:1129–1137.
  • Kirschner R, Rosenberg T, Schultz-Heienbrok R; et al. RPGR transcription studies in mouse and human tissues reveal a retina-specific isoform that is disrupted in a patient with X-linked retinitis pigmentosa. Hum Mol Genet. 1999;8(8):1571–15781.
  • Bennett SR, Folk JC, Kimura AE; et al. Autosomal dominant neovascular inflammatory vitreoretinopathy. Ophthalmology. 1990;97:1125–1135. discussion 1135–1126.
  • Stone EM, Kimura AE, Folk JC; et al. Genetic linkage of autosomal dominant neovascular inflammatory vitreoretinopathy to chromosome 11q13. Hum Mol Genet. 1992;1:685–689.
  • Mahajan VB, Skeie JM, Bassuk AG; et al. Calpain-5 mutations cause autoimmune uveitis, Retinal Neovascularization, and photoreceptor degeneration. PLoS Genet. 2012;8(10):e1003001.
  • Schaefer KA, Toral MA, Velez G; et al. Calpain-5 expression in the retina localizes to photoreceptor synapses. Invest Ophthalmol Vis Sci. 2016;57(6):2509–2521.
  • Bassuk AG, Yeh S, Wu S; et al. Structural modeling of a novel CAPN5 mutation that causes uveitis and neovascular retinal detachment. PLoS ONE. 2015;10(4):e0122352.
  • Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler Transform. Bioinformatics. 2009;25(14):1754–1760.
  • Rimmer A, Phan H, Mathieson I; et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat Genet. 2014;46(8):912–918.
  • Exome Aggregation Consortium (ExAC), Cambridge, MA. URL: http://exac.broadinstitute.org. Accessed: 26 10 2016.
  • MacLaren RE, Lightman SL. Variable phenotypes in patients diagnosed ith idiopathic multifocal chroiditis. Clin Exp Ophthalmol. Apr 2006;34(3):233–238.
  • Zatz M, Starling A. Calpains and disease. N Engl J Med. 2005;352:2413–2423.
  • Syntichaki P, Xu K, Driscoll M; et al. Specific aspartyl and calpain proteases are required for neurodegeneration in C. elegans. Nature. 2002;419:939–944.
  • Tlucek PS, Folk JC, Orien JA; et al. Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy. Arch Ophthalmol. 2012;130(11):1395–1401.
  • Tlucek PS, Folk JC, Sobol WM; et al. Surgical management of fibrotic encapsulation of the fluocinolone acetonide implant in CAPN5-associated proliferative vitreoretinopathy. Clin Ophthalmol. 2013;7:1093–1098.
  • Wert KJ, Skeie JM, Bassuk AG; et al. Functional validation of a human CAPN5 exome variant by lentiviral transduction into mouse retina. Hum Mol Genet. 2014;23(10):2665–2677.
  • Wert KJ, Bassuk AG, Wu W-H; et al. CAPN5 mutation in hereditary uveitis: the R243L mutation increases calpain catalytic activity and triggers intraocular inflammation in a mouse model. Hum Mol Genet. 2015;24(16):4584–4598.
  • Franz T, Winckler L, Boehm T; et al. CAPN5 is expressed in a subset of T cells and is dispensable for development. Mol Cell Biol. 2004;24:1649–1654.
  • Imai S, Shimazawa M, Nakanishi T; et al. Calpain inhibitor protects cells against light-induced retinal degeneration. J Pharmacol Exp Ther. 2010;335:645–652.
  • David J, Melamud A, Kesner L; et al. A novel calpain inhibitor for treatment of transient retinal ischemia in the rat. Neuroreport. 2011;22:633–636.
  • Nguyen AT, Campbell M, Kenna PF; et al. Calpain and photoreceptor apoptosis. Adv Exp Med Biol. 2012;723:547–552.
  • Ozaki T, Nakazawa M, Yamashita T; et al. Intravitreal injection or topical eye-drop application of a mu-calpain C2L domain peptide protects against photoreceptor cell death in Royal College of Surgeons’ rats, a model of retinitis pigmentosa. Biochim Biophys Acta. 2012;1822:1783–1795.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.